Severe hypertriglyceridemia following sirolimus use in an infant

Abstract Inhibitors of mammalian target of rapamycin function to downregulate cell growth and proliferation and have off‐label use in pediatrics for vascular malformations. Hypertriglyceridemia is a known side effect of mammalian target of rapamycin (mTOR) inhibitors. Further studies to better understand the incidence and treatment of hypertriglyceridemia in infants and neonates are warranted.